Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitris Repantis

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Neuropharmacology|July 26, 2012
Non-pharmacological cognitive enhancementMartin Dresler, Anders Sandberg, Kathrin Ohla, et al.
Psychopharmacology|June 10, 2026
Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method studyJulian Kirsch, Christopher Poppe, Anne Beck, et al.
EMBO Reports|January 16, 2013
Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individualsCynthia Forlini, Wayne Hall, Bruce Maxwell, et al.
Psychiatry Research|July 19, 2015
Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic reviewGuillaume Fond, Jean-Arthur Micoulaud-Franchi, Lore Brunel, et al.
Frontiers in Public Health|February 26, 2021
A Central Clearing Clinic to Provide Mental Health Services for Refugees in GermanyMalek Bajbouj, Patricia Panneck, Sibylle-Maria Winter, et al.
Journal of Affective Disorders|March 25, 2026
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|October 11, 2025
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|December 20, 2024
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|February 5, 2023
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of lifeGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
The New England Journal of Medicine|November 2, 2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major DepressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Neuropharmacology|July 26, 2012
Non-pharmacological cognitive enhancementMartin Dresler, Anders Sandberg, Kathrin Ohla, et al.
Psychopharmacology|June 10, 2026
Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method studyJulian Kirsch, Christopher Poppe, Anne Beck, et al.
EMBO Reports|January 16, 2013
Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individualsCynthia Forlini, Wayne Hall, Bruce Maxwell, et al.
Psychiatry Research|July 19, 2015
Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic reviewGuillaume Fond, Jean-Arthur Micoulaud-Franchi, Lore Brunel, et al.
Frontiers in Public Health|February 26, 2021
A Central Clearing Clinic to Provide Mental Health Services for Refugees in GermanyMalek Bajbouj, Patricia Panneck, Sibylle-Maria Winter, et al.
Journal of Affective Disorders|March 25, 2026
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|October 11, 2025
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|December 20, 2024
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|February 5, 2023
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of lifeGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
The New England Journal of Medicine|November 2, 2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major DepressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Pageof 3